Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $995.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price upped by research analysts at Guggenheim from $975.00 to $995.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s target price points to a potential upside of 41.25% from the company’s current price.

A number of other brokerages have also recently weighed in on REGN. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Piper Sandler started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $826.59.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $2.63 during trading hours on Friday, reaching $704.44. 165,261 shares of the company’s stock were exchanged, compared to its average volume of 743,545. The company has a market capitalization of $74.47 billion, a P/E ratio of 17.18, a price-to-earnings-growth ratio of 1.58 and a beta of 0.40. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.15 and a debt-to-equity ratio of 0.06. The business’s 50-day simple moving average is $756.81 and its two-hundred day simple moving average is $735.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same period last year, the firm posted $8.22 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals will post 35.98 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 3,774 shares of company stock valued at $2,942,738. Company insiders own 7.02% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. WPG Advisers LLC lifted its position in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares in the last quarter. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $27,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $29,000. Finally, Board of the Pension Protection Fund bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 beat and buyback — REGN topped Q1 estimates (revenue ~$3.61B, EPS beat) and announced a $3 billion share repurchase, which supports EPS and signals capital-return confidence. Analysts Cut Forecasts After Q1 (Benzinga)
• Positive Sentiment: Strong product growth drivers — management cited continued strength in Dupixent and growth in Eylea HD in some markets, underpinning near-term revenue momentum. Zacks: Q1 Earnings Top
• Positive Sentiment: Pipeline & milestones — progress in the C5 program (pivotal PNH enrollment, positive phase III for cemdisiran) could drive multi?indication upside and future approvals. C5 Milestones (Yahoo)
• Positive Sentiment: Dividend — REGN declared a quarterly dividend ($0.94 per share), adding a modest yield and steady cash-return signal to shareholders.
• Neutral Sentiment: Analyst price-target moves — several shops trimmed targets (RBC, Wells Fargo, Truist) but ratings largely remain in the buy/overweight/equal?weight range, leaving mixed guidance on upside. Benzinga: Analyst Price-Target Changes
• Neutral Sentiment: Long-term valuation view — some outlets (Zacks) still flag REGN as a top value/growth pick for long-term investors, suggesting the pullback may be a buying opportunity for patient holders. Zacks: Long-Term Value Thesis
• Neutral Sentiment: Mixed quarter financials — revenue rose ~19% YoY but net income fell ~10% to $727M, highlighting margin and expense dynamics investors should watch. Pharma?Tech: Q1 Net Income
• Negative Sentiment: U.S. Eylea HD shortfall — U.S. sales of high?dose Eylea missed expectations, raising concerns about near?term ophthalmology revenue and increased competition. Yahoo: Eylea Shortfall
• Negative Sentiment: Market reaction & analyst cuts — despite the beat, the stock fell on investor concerns and several analysts trimmed forecasts and targets, creating downward pressure. Seeking Alpha: Stock Drops Despite Q1 Beat

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.